NexImmune

NexImmune is an emerging biopharmaceutical company dedicated to developing a new generation of immunotherapies based on our proprietary AIM™ technology. This nanotechnology platform, initially developed by Johns Hopkins University, serves as the foundation for an innovative approach to immunotherapy that coordinates targeted T-cell responses against diseases by stimulating the body's own immune system. At the core of the AIM technology are artificial antigen-presenting cells (aAPC), which present antigens to T cells, thereby triggering a highly targeted treatment driven by the patient’s immune system.